| Business Summary | | American
Biogenetic
Sciences,
Inc.
(ABS)
is
a
development
stage
company
engaged
in
researching,
developing
and
marketing
cardiovascular
and
neurobiology
products
for
commercial
development.
The
Company's
products
are
designed
for
in
vitro
and
in
vivo
diagnostic
procedures
and
therapeutic
drugs.
The
Company's
therapeutic
products
have
been
identified
for
the
treatment
of
epilepsy,
migraine
and
mania
and
neurodegenerative
diseases.
At
the
present
time
ABS'
principal
products
or
activities
include
the
Thrombus
Precursor
Protein
diagnostic
test;
Functional
Intact
Fibrinogen
diagnostic
test;
antigen-free
technology;
therapeutic
neurocompounds;
in
vitro
diagnostic
products
for
infectious
and
auto-immune
disease;
and
mouse
serum. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | American
Biogenetic
Sciences
Inc.
engages
in
the
research
and
development
of
cardiovascular
and
neurobiology
products
for
commercial
development.
For
the
six
months
ended
6/30/01,
revenues
fell
38%
to
$887
thousand.
Net
loss
available
to
Common
fell
47%
to
$2.1
million.
Revenues
reflect
decreased
royalties
and
license
fees.
Lower
loss
reflects
decreased
professional
service
and
personnel
costs
and
the
absence
of
a
$2.5
million
preferred
dividend
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Alfred Roach, 85 Chairman,
CEO | $250K | -- | Josef Schoell, 51 Pres,
COO, Director | 120K | $198K | Ellena Byrne, 50 Exec.
VP | -- | -- | James McLinden, Ph.D., 50 Sr.
VP and CSO | -- | -- | Timothy Roach, 54 Treasurer,
Sec. | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|